Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PBM Reform Bill Reducing Cost Sharing In Part D Clears Senate Panel Without Biosimilar Policies

Executive Summary

Finance Committee is hoping to attach pharmacy benefit manager reform legislation to end-of-year budget legislation but the prospect is unpredictable at this point.

You may also be interested in...

Rx Rebating Bills In House, Senate Come Into Alignment As Passage Likely Punted to 2024

Legislation to delink PBM payments from drug prices advances in House Energy and Commerce health subcommittee, putting a key pharma priority closer to the finish line. Whether patients will see any benefit remains a worry.

The ‘Rebate Rule’ Reborn? US Senate Bill Would Test Price Pass-Throughs

A plan to ban rebates in the US Medicare outpatient drug program was a signature policy proposal of the Trump Administration – but has never been implemented. A Senate bill tests a different approach to the same goal of ensuring that price concessions by manufacturers translate into lower prices charged at the pharmacy counter.

Part D Cost Sharing Based On Net Price, Boost For ‘High Discount’ Biosimilars Proposed In Draft Bill

Senate Finance Committee’s PBM legislation would essentially pass through rebate value at the pharmacy counter for some drugs, block situations where beneficiaries pay more than plans and reward biosimilars that have list prices substantially below their reference products.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts